Payment overview · 2025
General Payments
$536.05
29 reported records · 12 companies
Healthcare provider profile · identity verified
Dean E. Beckman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JASPER, IN · NPI 1497753016
Verified facts
What the public records show
CMS Open Payments records show Dean E. Beckman, M.D. received $536.05 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.61 | 16.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.56 | 16.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.72 | 13.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.94 | 11.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.25 | 7.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.51 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.47 | 5.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.54 | 5.3% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.86 | 5.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.24 | 5.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.62 | 3.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.73 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $536.05 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.61 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.56 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.94 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.94 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.02 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.25 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.54 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.24 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 114 |
| Lisinopril | Lisinopril | 396 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 93 |
| Losartan Potassium | Losartan Potassium | 352 | 98 |
| Simvastatin | Simvastatin | 330 | 85 |
| Metformin Hcl | Metformin Hcl | 324 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 68 |
| Sertraline Hcl | Sertraline Hcl | 248 | 58 |
| Omeprazole | Omeprazole | 244 | 71 |
| Atenolol | Atenolol | 186 | 45 |
| Glimepiride | Glimepiride | 186 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 47 |
| Furosemide | Furosemide | 154 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 41 |
| Prednisone | Prednisone | 135 | 93 |
| Alendronate Sodium | Alendronate Sodium | 133 | 38 |
| Allopurinol | Allopurinol | 128 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 127 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 28 |
| Gabapentin | Gabapentin | 103 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 37 |
| Eliquis | Apixaban | 77 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 41 |
| Lorazepam | Lorazepam | 73 | suppressed |
| Ozempic | Semaglutide | 73 | suppressed |
| Meloxicam | Meloxicam | 72 | 22 |
| Trazodone Hcl | Trazodone Hcl | 71 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 11 |
| Jardiance | Empagliflozin | 70 | 16 |
| Potassium Chloride | Potassium Chloride | 70 | 18 |
| Famotidine | Famotidine | 68 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 17 |
| Cephalexin | Cephalexin | 64 | 38 |
| Cefuroxime | Cefuroxime Axetil | 60 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Finasteride | Finasteride | 49 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 11 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Carvedilol | Carvedilol | 39 | 14 |
| Tramadol Hcl | Tramadol Hcl | 39 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 11 |
| Methimazole | Methimazole | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Klonopin | Clonazepam | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $536.05 · 29 records | ABBVIE INC. | Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZURZUVAE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error